Abstract:Introduction: Rectal cancer is potentially curable condition but usually carries a poor prognosis because of local recurrence or distant metastasis. Neoadjuvant chemoradiation therapy (CRT) is often used for patients who have increased risk of circumferential resection margin involvement at surgery. Non-invasively methods for monitoring tumor response to preoperative CRT are mainly imaging based. New functional imaging techniques can potentially improve accuracy including diffusion-weighted imaging (DWI), dynamic contrast-enhanced MRI (DCE-MRI) and F-fluorodeoxyglucose (F-FDG) PET/CT. An increase of apparent diffusion coefficient (ADC), a quantitative parameter measured on DWI, suggests treatment-induced cell lysis and necrosis during the course of CRT. However, increase in ADC can also result from change in vessel permeability due to radiation therapy. For this, DCE-MRI may provide useful information regarding vascular permeability. On the other hand, late decrease in ADC is usually considered result of tissue compaction and fibrosis. But presence of residual active disease can also decrease ADC. Therefore, DWI alone might not distinguish between residual active disease and treatment-induced tumor fibrosis, which can be differentiated using PET/CT. The aim of this study was to investigate DWI, DCE-MRI and PET/CT for response assessment over a course of pre-operative combined CRT for primary rectal adenocarcinoma, to see if the combination of different techniques can best predict biological behavior and clinical outcome. Materials and Methods: 8 consecutive patients (6 men, 2 women, 54-73 years) suffering from rectal cancer of stage T3 or above were included in this study. Each patient received neoadjuvant chemoradiation preoperatively with 1.8Gy/fr daily 5fr/wk up to 50.4Gy. They underwent both MRI and PET/CT scans at three time points: baseline (before CRT), early mid treatment (2-week after start of CRT), and post-treatment (6-week after conclusion of CRT). All MRI and PET/CT were performed within one week interval (mean time interval: 2±1 days) at each time point. Total mesorectal excision (TME) was performed after completion of CRT and imaging scans. Radiographic changes were classified according to the Response Evaluation Criteria in Solid Tumors group (RECIST). Response was defined if complete or partial response was observed. Non-response was defined if progress or stable disease was observed. The differences of the imaging parameters between responders and non-responders were tested using the nonparametric Mann-Whitney test. The significance of changes of imaging parameters during therapy within a patient group was tested using a paired Wilcoxon test. Results: Patients and post-treatment changes are shown in table 1. Imaging parameters between response group and non-response group at different time points are shown in table 2. In figure 1, ADCmean changes of patients with data from all three time points in response group (solid lines) and non-response group (dotted lines) are shown in similar pattern except patient # 3, which was post-surgically confirmed to be mucous tumor. Mucinous tumors were known to behave differently and do not respond well to CRT, as suggested by the static ADCmean from baseline to the intermediate time point. K changes of patients with data from all three time points in response group (solid lines) are opposite to that of patients in non-response group (dotted lines) in figure 2. The change of mean K is consistent with the sharp increase of ADC from baseline to the intermediate time point for non-response group, suggesting the contributing value of increased vascular permeability to ADC measurement. In figure 3, SUVmax changes of patients in response group (solid lines) and non-response group (dotted lines) decreased from baseline to the final time point. However, there was no significant difference of SUVmax between responders and non-responders at the final time point. However, due to small sample size, we did not get any statistical significant results at present. Conclusion: From the limited data available from this study, we hypothesize that (1) in the early phase of CRT, the increase of ADC in responders represent treatment-induced apoptotic cell death and necrosis, whereas the increase of ADC in non-responders are result of vessel permeability after radiation. (2) The inflammation-induced SUV increase was not observed in both responders and non-responders during the course of CRT, supporting previous study that inflammation-induced SUV may have minimal impact in rectal cancer, or due to the partial volume effect to small lesions. (3) Future study with large cohort is needed to make statistical conclusion for our findings.

The Role Of Sequential 18(F)-Fdg Pet/Ct In Predicting Tumour Response After Preoperative Chemoradiation For Rectal Cancer

The Role of 18F-FDG PET/CT in Predicting Tumor Response after Preoperative Chemo-radiation Therapy for Rectal Cancer

18F-FDG PET/CT for the Early Prediction of the Response Rate and Survival of Patients with Recurrent or Metastatic Breast Cancer.

Predicting Response to Radiotherapy in Tumors with PET/CT: when and How?

The role of 18F-FDG PET/CT in predicting the pathological response to neoadjuvant PD-1 blockade in combination with chemotherapy for resectable esophageal squamous cell carcinoma

Fluorodeoxyglucose Positron Emission Tomography for Evaluating Early Response During Neoadjuvant Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma

The Value of PET/CT in Early Predicting Pathological Response of Locally Advanced Rectal Cancer after Neoadjuvant Radiochemotherapy

Restaging of rectal cancer with hybrid positron emission tomography magnetic resonance imaging after preoperative chemoradiotherapy

The reduction of 18F-FDG uptake ability of tumor tissue after neoadjuvant chemoradiotherapy in locally advanced rectal cancer can effectively reflect the degree of tumor regression

Tumor SUVmax Normalized to Liver Uptake on 18F-FDG PET/CT Predicts the Pathologic Complete Response After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

18 F-FDG PET/CT predicts the role of neoadjuvant immunochemotherapy in the pathological response of esophageal squamous cell carcinoma

Combined use of DWI , DCE-MRI , and PET / CT in treatment response for preoperative chemoradiation in primary rectal adenocarcinoma

18F-FLT PET/CT in Predicting Response to Chemoradiotherapy in Esophageal Squamous Cell Cancer: Comparison with 18F-FDG PET/CT

479. THE ROLE OF PET/CT IN PREDICTING THE PATHOLOGICAL RESPONSE TO NEOADJUVANT IMMUNOCHEMOTHERAPY FOR RESECTABLE ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Utility of 18F-FDG PET/CT Uptake Values in Predicting Response to Neoadjuvant Chemoimmunotherapy in Resectable Non-Small Cell Lung Cancer.

Spatial-Temporal [18F]FDG-PET Features for Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiation Therapy

SU‐E‐J‐254: Evaluating the Role of Mid‐Treatment and Post‐Treatment FDG‐PET/CT in Predicting Progression‐Free Survival and Distant Metastasis of Anal Cancer Patients Treated with Chemoradiotherapy

The Predictive Value of Pretreatment 18-F-FDG-PET-CT in Locally Advanced Nasopharyngeal Cancer Patients Treated Definitively with Induction Chemotherapy Followed by Concurrent Chemo-Radiotherapy

The utility of 18F-FDG PET/CT for predicting the pathological response and prognosis to neoadjuvant immunochemotherapy in resectable non-small-cell lung cancer

The Comparison of 18F-Alfatide PET/CT and 18F-FDG PET/CT in Predicting Chemoradiotherapy Sensitivity in Patients with Advanced Non-Small Cell Lung Cancer.

The comparison of <sup>18</sup>F-alfatide PET/CT and <sup>18</sup>F-FDG PET/CT in predicting chemoradiotherapy sensitivity in patients with advanced non-small cell lung cancer.